These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20148906)

  • 21. Serum N-terminal osteocalcin is a good indicator for estimating responders to hormone replacement therapy in postmenopausal women.
    Chen JT; Hosoda K; Hasumi K; Ogata E; Shiraki M
    J Bone Miner Res; 1996 Nov; 11(11):1784-92. PubMed ID: 8915787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiazolidinediones.
    Mascitelli L; Pezzetta F
    N Engl J Med; 2005 Jan; 352(2):205-7; author reply 205-7. PubMed ID: 15651125
    [No Abstract]   [Full Text] [Related]  

  • 23. Biomarkers of bone health and osteoporosis risk.
    Eastell R; Hannon RA
    Proc Nutr Soc; 2008 May; 67(2):157-62. PubMed ID: 18412989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone metabolism in type 2 diabetes and role of thiazolidinediones.
    Vestergaard P
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):125-31. PubMed ID: 19300092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Assessment of the alkaline (ALP) and acid phosphatase (ACP) in the blood serum of rats during experimental postmenopausal osteoporosis].
    Rahnama M; Swiatkowski W; Zareba S
    Rocz Panstw Zakl Hig; 2002; 53(3):283-91. PubMed ID: 12621884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
    Grey A; Bolland M; Gamble G; Wattie D; Horne A; Davidson J; Reid IR
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1305-10. PubMed ID: 17264176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical markers as predictors of rates of bone loss after menopause.
    Rogers A; Hannon RA; Eastell R
    J Bone Miner Res; 2000 Jul; 15(7):1398-404. PubMed ID: 10893690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period.
    Nguyên-Pascal ML; Thomas JL; Bergougnoux L; Garnero P; Drapier-Faure E; Delmas PD
    Climacteric; 2005 Jun; 8(2):136-45. PubMed ID: 16096169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of Migu tablet on bone mineral density, serum matrix metalloproteinase-2 level and bone metabolic markers in postmenopausal osteoporosis].
    Dai Y; Shen L
    Zhongguo Zhong Yao Za Zhi; 2007 Nov; 32(22):2409-12. PubMed ID: 18257271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of simvastatin on serum cytokine levels and bone metabolism in postmenopausal subjects: negative correlation between TNF-alpha and anabolic bone parameters.
    Tikiz C; Unlü Z; Tikiz H; Ay K; Angin A; Onur E; Var A; Tüzün C
    J Bone Miner Metab; 2004; 22(4):365-71. PubMed ID: 15221496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biochemical markers of bone remodeling: recent data of their applications in managing postmenopausal osteoporosis].
    Bahlous A; Kalai E; Hadj Salah M; Bouzid K; Zerelli L
    Tunis Med; 2006 Nov; 84(11):751-7. PubMed ID: 17294906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes of bone formation markers osteocalcin and bone-specific alkaline phosphatase in postmenopausal women with osteoporosis.
    Lumachi F; Ermani M; Camozzi V; Tombolan V; Luisetto G
    Ann N Y Acad Sci; 2009 Sep; 1173 Suppl 1():E60-3. PubMed ID: 19751416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
    Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
    Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes.
    Li H; Cui R; Cai H; Wu G; Lv Z; Sheng C; Cheng X; Li F; Yu Y
    J Bone Miner Metab; 2010; 28(1):77-81. PubMed ID: 19603247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study.
    Tikiz C; Tikiz H; Taneli F; Gümüşer G; Tüzün C
    Clin Rheumatol; 2005 Sep; 24(5):447-52. PubMed ID: 15742122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type 2 diabetes, thiazolidinediones: bad to the bone?
    Watts NB; D'Alessio DA
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3276-8. PubMed ID: 16960122
    [No Abstract]   [Full Text] [Related]  

  • 38. Thiazolidinediones: antidiabetic agents with effects on bone.
    Debiais F
    Joint Bone Spine; 2009 May; 76(3):221-3. PubMed ID: 19362505
    [No Abstract]   [Full Text] [Related]  

  • 39. [Do thiazolidinediones harm skeletal integrity?].
    Takeuchi Y
    Clin Calcium; 2008 May; 18(5):650-5. PubMed ID: 18445884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biochemical markers for bone metabolism--overview].
    Nakatsuka K; Nishizawa Y
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():220-7. PubMed ID: 11979911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.